Recruiting

Observational Study

Sponsor:

University of Oxford

Code:

NCT01066208

Conditions

Wegener's Granulomatosis

Microscopic Polyangiitis

Churg Strauss Syndrome

Polyarteritis Nodosa

Giant Cell Arteritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Vasculitis is group of diseases where inflammation of blood vessels is the common feature. Patients typically present with fever, fatigue, weakness and muscle and joint aches. These symptoms are very common among many different diseases, not just vasculitis. A clustering of other symptoms, physical examination findings, blood tests, radiology and biopsy help make the diagnosis. There are currently no criteria to help doctors make a diagnosis of vasculitis when a patient presents with these non specific symptoms and they are reliant on previous experience and disease definitions. One of the aims of this project is to develop diagnostic criteria for the primary systemic vasculitides (granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, Churg Strauss syndrome, polyarteritis nodosa, giant cell arteritis, Takayasu arteritis). We, the investigators, will do this by studying a large group of patients with vasculitis and comparing them to a large group of patients that present in a similar way, but do not have vasculitis. By comparing the 2 groups we will create a list of items to differentiate between vasculitis and 'vasculitis mimics'.

We also aim to update the current classification criteria. Classification criteria are used to group patients into different types of vasculitis, once a diagnosis of vasculitis has been made, and are useful for studying patients in clinical trials with similar or identical diseases. The current classification criteria (American college of Rheumatology 1990 criteria) were developed 20 years ago, before the availability of some important diagnostic tests (e.g. antineutrophil cytoplasmic antibodies \[ANCA\]), and are now not consistent with some of the current disease definitions. Therefore to progress future research in vasculitis, it is important that the classification criteria are updated. We will recruit 260 patients with each of the 6 types of vasculitis and compare them with 1300 controls (patients with the 5 other types of vasculitis), in order to determine the optimal combination of symptoms, signs and investigations that classify each person into the appropriate group.

Conditions

Wegener's Granulomatosis

Microscopic Polyangiitis

Churg Strauss Syndrome

Polyarteritis Nodosa

Giant Cell Arteritis

Study ID

NCT01066208

Start date

Jan, 2011

Status verified date

Aug, 2016

Completion date

Dec, 2018

Anticipated

Primary completion date

Dec, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria for Classification criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Presumed diagnosis of a primary systemic vasculitis.

Exclusion criteria for classification criteria:

1. Patients < 18 years of age.
2. Inability to provide informed consent.
3. Hepatitis B or C
4. Co-morbidities that explain the clinical symptoms and signs on which the diagnosis of vasculitis is made. E.g. infection, tumour, other inflammatory condition, etc.

Inclusion criteria for diagnostic criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Suspected diagnosis of a primary systemic vasculitis

Inclusion criteria for controls group for diagnostic criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Patients presenting to secondary care with one of the following clinical presentations: I.Multi-system disease. Presentation of disease with at least 2 organs involved. II.Pulmonary-renal syndrome. Defined as haemoptysis / pulmonary haemorrhage with acute renal impairment. III.Acute renal failure IV.Acute respiratory distress. V.Chronic upper airways symptoms and signs. VI.Inflammatory polyarthritis. VII.Fever of unknown origin. VIII.Acute or chronic abdominal pain IX.Hypertension. X.Referred to secondary care with suspicion of vasculitis but confirmed not to have vasculitis. XII.New onset headache. XIII.Jaw or tongue pain. XIV.Sudden visual loss. XV.Limb claudication. XVI.Aortic aneurysm >5cm.

Exclusion Criteria for diagnostic criteria:

1. Patients under the age of 18
2. Patient or next of kin unable or unwilling to provide informed consent or assent.

Study Design

Enrollment

3588 participants

Anticipated

Interventions and Outcome Measures

Arms

WG classification

Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

MPA classification

Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

CSS classification

Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

PAN classification

Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

Control Classification

For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

WG diagnostic

Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

MPA diagnostic

Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

CSS diagnostic

Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

PAN diagnostic

Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

Control diagnostic

Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

GCA classification

Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

TAK classification

Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

GCA diagnostic

Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

TAK diagnostic

Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

Primary outcome measure

  • Develop new diagnostic and classification criteria for ANCA associated vasculitis and polyarteritis nodosa [ Time Frame: 3 years ]

Central Contacts and Locations

Locations

University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35233

Contacts

Angelo Gaffo

agaffo@uab.edu

Principal Investigator:

Angelo Gaffo

Cedars-Sinai Medical Center, LA

Recruiting

Los Angeles, California, United States, 90048

Contacts

Michael Weisman

Weisman@cshs.org

Principal Investigator:

Michael Weisman

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143-0500

Contacts

Principal Investigator:

Sharon Chung

University of Maryland

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

Principal Investigator:

Jamal Mikdashi

Vasculitis Center, Boston University School of Medicine

Recruiting

Boston, Massachusetts, United States, 02118

Contacts

Principal Investigator:

Peter Grayson

University of Michigan, Internal Medicine

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

William J McCune

jmccune@med.umich.edu

Principal Investigator:

Professor William J McCune

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Principal Investigator:

Eric Matteson

Dartmouth-Hitchcock Medical Centre, Lebanon, NH

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Principal Investigator:

Daniel A Albert

Cleveland Clinic

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Carol Langford

LANGFOC@ccf.org

Principal Investigator:

Leonard Calabrese

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Peter A Merkel

pmerkel@upenn.edu

Principal Investigator:

Peter A Merkel

University of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15261

Contacts

Principal Investigator:

Kim Liang

University of Manitoba

Recruiting

Winnipeg, Manitoba, Canada, R3A 1M4

Contacts

Navjot Dhindsa

ndhindsa@hsc.mb.ca

Principal Investigator:

Navjot Dhindsa

St Joseph's Healthcare

Recruiting

Hamilton, Ontario, Canada

Contacts

Principal Investigator:

Nader Khalidi

University of Ottawa

Recruiting

Ottawa, Ontario, Canada, K1N 6N5

Contacts

Principal Investigator:

Nataliya Milman

Mount Sinai Hospital, Toronto

Recruiting

Toronto, Ontario, Canada, ON M5T 2S8

Contacts

Principal Investigator:

Simon Carette

McGill University

Recruiting

Montreal, Quebec, Canada, H3A 0G4

Contacts

Principal Investigator:

Christian Pineau

Sherbrooke University Hospital Centre

Recruiting

Sherbrooke, Quebec, Canada, J1H 5N4

Contacts

Principal Investigator:

Patrick Liang

St Joseph's Healthcare London, Ontario

Recruiting

Ontario, Canada

Principal Investigator:

Lillian Barra

More Information

Sponsor

University of Oxford

Last update posted

Aug 19, 2016

Last verified

Aug, 2016

Keywords

  • Classification criteria
  • Diagnostic criteria

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Oxford on 2016-08-19.